Maxillary Sinus Squamous Cell Carcinoma: A Clinical Study

Abstract

We retrospectively analyzed the clinical characteristics and treatment outcomes of patients with maxillary sinus squamous cell carcinoma. The patients were 22 newly diagnosed cases of maxillary sinus squamous cell carcinoma who were treated at our institute between 2005 and 2016. There were 19 males and 3 females, ranging in age from 45 to 83 years (average age: 64.2 years). Our treatment protocol was as follows: All patients received chemoradiotherapy with weekly superselective intra-arterial administration of cisplatin (radiotherapy and concomitant intra-arterial cisplatin [RADPLAT]; 100–120 mg/body). Good responders at 30 to 40 Gy received additional radiotherapy (RADPLAT, ordinary chemoradiotherapy, or radiotherapy alone) until the total dose reached 72 Gy, whereas the other patients underwent radical surgery (partial maxillectomy, total maxillectomy, or extended total maxillectomy). The latter patients were given postoperative (chemo)radiotherapy up to a total dose of 72 Gy, when histopathological examination revealed insufficient resection or a positive surgical margin. The overall 5-year crude and disease-specific survival rates determined by the Kaplan–Meier method were 47.8 and 56.9%, respectively. The crude survival rate tended to be higher in T3 patients than in T4 patients (80.0 vs. 29.9%, p = 0.077). Seven patients died of the primary disease. The cause of death was distant metastasis in four patients, recurrence of the primary lesion in two patients, and cervical lymph node metastasis in one patient. These results suggest the importance of early detection and early treatment, and of the development of more effective treatment for advanced maxillary cancers, to further improve the survival rate.

Keywords

maxillary sinus squamous cell carcinoma - treatment outcome - survival rate - superselective intra-arterial chemoradiotherapy

Note

This study was approved by the Ethics Committee of the University of Occupational and Environmental Health.

• References

• 1 Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92 (12) 3012-3029
• 2 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Central Nervous System Cancers Version 2. 2011;2:19–21. Available at: http://oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf . Accessed September 1, 2018
• 3 Tachida K, Yoshida F, Saijo S. , et al. A clinical study of maxillary sinus malignancy. Japanese J Head Neck Cancer 2004; 30: 8-12
• 4 Yamashita T, Fujii M, Ishiguro R. , et al. [Statistical analysis of maxillary sinus squamous cell carcinoma]. Nippon Jibiinkoka Gakkai Kaiho 2002; 105 (06) 732-740
• 5 Toshimura T, Ohara H, Ashizawa K. , et al. Clinical assessment of paranasal malignant tumor. Jibi Inkoka Tembo 2013; 56: 49-53
• 6 Ogawa T. [A clinico-pathological study of adenocarcinomas of the nasal cavity and paranasal sinuses]. Nippon Jibiinkoka Gakkai Kaiho 1989; 92 (03) 317-333
• 7 Shiga K. What is the treatment selection for patients with T3–4 maxillary sinus squamous cell carcinoma? From the perspective of super-selective arterial infusion. JOHNS 2009; 25: 1472-1475
• 8 Maeda A, Chijiwa H, Sakamoto K, Miyajima Y, Umeno H, Nakashima T. [Clinical study of cervical lymph node metastasis in maxillary cancer patients]. Nippon Jibiinkoka Gakkai Kaiho 2008; 111 (06) 486-489
• 9 Rikimaru F, Matsuo M, Higaki Y. , et al. The treatment of maxillary sinus squamous cell carcinoma at our department. J Japan Soc Head Neck Surg 2011; 21: 145-149
• 10 Harbo G, Grau C, Bundgaard T. , et al. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36 (01) 45-50
• 11 Asakura K, Himi T, Harabuchi Y. , et al. A clinical study of maxillary carcinoma. Pract Otorhinolaryngol (Basel) 1995; 84: 87-95
• 12 Rasch CR, Hauptmann M, Schornagel J. , et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer 2010; 116 (09) 2159-2165
• 13 Homma A. Superselective high-dose cisplatin arterial infusion with concomitant radiotherapy. Japanese J Head Neck Cancer 2012; 22: 29-31
• 14 Koike S, Nasu T, Ishida A. , et al. Long-term outcomes and late complications of superselective intra-arterial chemotherapy for maxillary squamous cell carcinoma. Japanese J Head Neck Cancer 2010; 36: 483-487
• 15 Shiga K, Yokoyama J, Hashimoto S. , et al. Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg 2007; 136 (06) 1003-1009
• 16 Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 1992; 14 (05) 364-371
• 17 Yoshizaki T, Tsukatani T, Wakisaka N. , et al. Rapid intra-arterial chemoradiotherapy for the treatment of maxillary sinus cancer: the relationship with CDDP dose. Japanese J Head Neck Cancer 2007; 33: 434-438
• 18 Homma A, Onimaru R, Matsuura K. , et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase. Head Neck 2018; 40 (03) 475-484
• 19 Takahashi G, Mochizuki D, Sugiyama K. , et al. A single institution, retrospective study of superselective intra-arterial cisplatin and concomitant radiation for maxillary sinus squamous cell carcinomas [in Japanese]. Pract Otorhinolaryngol 2013; 136: 5-11
• 20 Noronha V, Patil VM, Joshi A. , et al. Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus. Chemother Res Pract 2014; 2014: 487872